EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment

Richard B Lipton iD, Pranav Gandhi, Kelley Myers, Cooper Bussberg, Jonathan Stokes, Stephanie J Nahas

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.14974 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, 2025. Written by Richard B Lipton and 5 co-authors. Institution: Department of Neurology, Albert Einstein College, Bronx, New York, USA. Major MEDLINE topics: Migraine Disorders, Patient Preference, Choice Behavior, Calcitonin Gene-Related Peptide Receptor Antagonists. Cited 6 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: AbbVie, Inc.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

This study was conducted among participants with episodic migraine, to (i) assess patient preferences for attributes associated with calcitonin gene‐related peptide‐targeting therapies to prevent migraine and (ii) predict the probability that a real‐world patient would prefer an atogepant‐like treatment profile over monoclonal antibody‐like profiles.

Background

Calcitonin gene‐related peptide‐targeting therapies have emerged as safe and effective first‐line preventive treatments for migraine. Given the expansion of the treatment landscape, it is important to understand what drives treatment choices among patients with migraine. However, few studies have quantified patient preferences for attributes of preventive treatments for migraine.

Methods

A discrete‐choice experiment survey was administered to adults (aged 18–80 years and

Subjects

MeSH terms (MEDLINE)

Migraine DisordersPatient PreferenceChoice BehaviorCalcitonin Gene-Related Peptide Receptor AntagonistsHumansAdultMaleMiddle AgedFemaleAgedYoung AdultAdolescentUnited StatesAged, 80 and overCalcitonin Gene-Related Peptide

Author keywords

atogepantcalcitonin gene‐related peptide‐targeting therapiesdiscrete‐choice experimentepisodic migrainepatient preferencespreventive migraine treatment

Substances

Calcitonin Gene-Related Peptide Receptor AntagonistsCalcitonin Gene-Related Peptide

Authors and institutions

  • Department of Neurology, Albert Einstein College, Bronx, New York, USA.
  • Health Economics and Outcomes Research, AbbVie, Inc., Chicago, Illinois, USA.
  • Health Preference Assessment, RTI Health Solutions, Research Triangle Park, North Carolina, USA.
  • Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

ORCID profiles: Richard B Lipton

Funding

  • AbbVie, Inc

Cite

APA

Lipton, R. B., Gandhi, P., Myers, K., Bussberg, C., Stokes, J., & Nahas, S. J. (2025). Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14974

Vancouver

Lipton RB, Gandhi P, Myers K, Bussberg C, Stokes J, Nahas SJ. Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14974

BibTeX
@article{Lipton2025,
  author = {Lipton, Richard B and Gandhi, Pranav and Myers, Kelley and Bussberg, Cooper and Stokes, Jonathan and Nahas, Stephanie J},
  title = {Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14974}
}
Start for free →